

46. (Reiterated) The method of claim 42 wherein the tumor or cancer is a pancreatic tumor.

47. (Reiterated) The method of claim 42 wherein the tumor or cancer is a vulval tumor.

48. (Reiterated) The method of claim 42 wherein the tumor or cancer is a thyroid tumor.

49. (Reiterated) The method of claim 42 wherein the tumor or cancer is a hepatic tumor.

50. (Reiterated) The method of claim 42 wherein the tumor or cancer is a sarcoma.

51. (Reiterated) The method of claim 42 wherein the tumor or cancer is a glioblastoma.

52. (Reiterated) The method of claim 42 wherein the tumor or cancer is a head and neck tumor.

53. (Reiterated) The method of claim 42 wherein the tumor or cancer is leukemia.

54. (Reiterated) The method of claim 42 wherein the tumor or cancer is a lymphoid malignancy.

Sub
C2
55. (Reiterated) The method of claim 42 wherein the anti-ErbB2 antibody cross-blocks binding of antibody 4D5 (ATCC CRL 10463) to ErbB2.

56. (Reiterated) The method of claim 42 wherein the anti-ErbB2 antibody cross-blocks binding of antibody 7C2 (ATCC HB-12215) or antibody 7F3 (ATCC HB-12216) to ErbB2.

Please cancel claims 57-58 without prejudice or disclaimer.

B2
59. (Amended) The method of claim 42 wherein a chemotherapeutic agent is administered to the patient in an amount effective to kill or inhibit growth of tumor cells in the patient.

60. (Reiterated) The method of claim 59 wherein the chemotherapeutic agent is selected from the group consisting of Doxorubicin, 5-

Fluorouracil, Cytosine arabinoside ("Ara-C"), Cyclophosphamide, Thiotepa, Busulfan, Cytosine, Methotrexate, Cisplatin, Melphalan, Vinblastine, Bleomycin, Etoposide, Ifosfamide, Mitomycin C, Mitoxantrone, Vincristine, Vinorelbine, Carboplatin, Teniposide, Daunomycin, Carminomycin, Aminopterin, Dactinomycin, Mitomycin, Esperamicins, Melphalan and other related nitrogen mustards, tamoxifen and onapristone.

B3 61. (Amended) The method of claim 42 wherein a growth inhibitory agent is administered to the patient in an amount effective to inhibit growth of tumor cells in the patient.

62. (Reiterated) The method of claim 61 wherein the growth inhibitory agent is selected from the group consisting of vincas, topo II inhibitors, doxorubicin, daunorubicin, etoposide, bleomycin, DNA alkylating agents, tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C.

Sub C3 63. (Reiterated) A method of treating a tumor or cancer characterized by overexpression or activation of ErbB2 comprising a first therapeutic regimen comprising administering an anti-ErbB2 antibody to a patient in an amount effective to kill or inhibit growth of tumor cells in the patient and a second therapeutic regimen comprising administering a growth inhibitory agent in an amount effective to inhibit growth of tumor cells in the patient, wherein the growth inhibitory agent is a vinca.

64. (Reiterated) The method of claim 63 wherein the vinca is selected from the group consisting of Vincristine, Vinblastine and Vinorelbine.

Sub C4 65. (Reiterated) The method of claim 63 wherein the anti-ErbB2 antibody cross-blocks binding of antibody 4D5 (ATCC CRL 10463) to ErbB2.

66. (Reiterated) The method of claim 63 wherein the anti-ErbB2 antibody cross-blocks binding of antibody 7C2 (ATCC HB-12215) or antibody 7F3 (ATCC HB-12216) to ErbB2.